Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Baylor researchers study outcomes and effectiveness of traumatic brain injury rehabilitation

For patients recovering from a traumatic brain injury (TBI), the rehabilitation process - compensating for changes in functioning, adaptation and even community reintegration - can be challenging.

6 Dec 2013

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

The Scleroderma Research Foundation today reported that researchers at The Johns Hopkins University have discovered that some cases of scleroderma are likely to have been initiated by cancer.

6 Dec 2013

Approaches to pain measurement used in cancer oncology clinical trials submitted to U.S. FDA

Pain is a common symptom and can be debilitating for patients with cancer. Clinically significant improvements in pain resulting from a cancer treatment can support drug approval and labeling claims in the United States, when it is adequately measured.

6 Dec 2013

Researchers identify biomarker that may accurately predict prostate cancer spread

Researchers at Vanderbilt University Medical Center and the University of Alberta in Canada have identified a biomarker for a cellular switch that accurately predicts which prostate cancer patients are likely to have their cancer recur or spread.

6 Dec 2013

Cancer triggers scleroderma, shows evidence

Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage.

6 Dec 2013

Alvotech to invests $250M in the development of biosimilar monoclonal antibodies

Alvotech, a powerful new player in the field of biopharmaceuticals, today announced plans to invest $250 million in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies.

5 Dec 2013

IDSA released new guideline for vaccination of immunocompromised hosts

A new guideline released Thursday by the Infectious Diseases Society of America (IDSA) notes that most people with compromised immune systems are especially vulnerable to illness and should receive the flu shot and other vaccinations.

5 Dec 2013

BIDMC study shows carbon monoxide may have a role to play in treating cancer

In recent years, research has suggested that carbon monoxide, the highly toxic gas emitted from auto exhausts and faulty heating systems, can be used to treat certain inflammatory medical conditions. Now a study led by a research team at Beth Israel Deaconess Medical Center (BIDMC) shows for the first time that carbon monoxide may also have a role to play in treating cancer.

4 Dec 2013

Lung cancer is costliest cancer in European Union

The total cost of cancer care across the European Union was an estimated € 126 billion in 2009, with lung cancer having the highest cost, at 15% of the total.

4 Dec 2013

Roche signs research collaboration and licensing agreement with Molecular Partners

Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners' DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer.

4 Dec 2013

Laboratoire Cerba launches noninvasive prenatal test in multiple countries

Sequenom, Inc., a life sciences company providing innovative testing and genetic analysis solutions, announced that Laboratoire Cerba has launched its validated noninvasive prenatal test to health care providers and their patients in France, Belgium, Luxembourg and portions of the Middle East and Africa.

4 Dec 2013

Health Media Network, Digital Blue Dog partner to create Oncology point-of-care network in the U.S.

Connecticut-based Health Media Network and Florida-based Digital Blue Dog have signed an agreement to exclusively represent DBD's Oncology Network, creating the largest Oncology specific and patient-centric point-of-care network in the U.S.

4 Dec 2013

VolitionRx's two-assay test can detect 85% of colorectal cancer, more than 50% of precancerous polyps

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today releases new data showing that when combining two of its proprietary NuQ assays into one test, they can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition’s two-assay test can detect more than 50% of precancerous polyps. These new findings come from its ongoing prospective study with CHU Dinant Godinne | UCL Namur Hospital in Belgium.

4 Dec 2013

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan.

4 Dec 2013

Allegiance Health, UMHS sign letter of intent to serve Jackson community

The University of Michigan Health System (UMHS) and Allegiance Health have signed a letter of intent to affiliate, with Allegiance Health becoming a member of the UMHS network.

4 Dec 2013

Cell Therapeutics concludes agreement with GKV-SV regarding reimbursement price of PIXUVRI

Cell Therapeutics, Inc. (CTI) announced today that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for PIXUVRI® (pixantrone).

4 Dec 2013

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis will present updates on its broad cancer portfolio with more than 240 abstracts at the upcoming American Society of Hematology (ASH) annual meeting and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

4 Dec 2013

Findings could have important implications for personalized treatment of colon cancer

A common observation in oncology is the phenomenon that a patient with a tumor receives a drug and responds very well, but after a few months the cancer comes back and is now resistant to previously administered chemotherapy. What happened? Many mechanisms contribute to explain this effect called "acquired resistance", but today the group Manel Esteller, Director of Epigenetics and Cancer Biology at the Bellvitge Biomedical Research Institute, ICREA researcher and Professor of Genetics at the University of Barcelona, describes in the official Journal of the National Cancer Research Center in the United States, The Journal of The National Cancer Institute, the existence of epigenetic differences that explain the lack of response of the tumor recurs.

4 Dec 2013

Presence of ERG protein in biopsied prostate tissue increases likelihood of cancer development

Researchers from Weill Cornell Medical College have shown that the presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. The discovery will likely help physicians decide how closely to monitor men potentially at risk for the cancer -- among the most confusing and controversial dilemmas in health care.

4 Dec 2013

CTCs serve as clinical tool to determine patient’s response to chemotherapy

Scientists from Granada have demonstrated, for the first time, that detecting circulating tumour cells (CTCs) in blood and studying the presence of certain genetic markers in them is a technique that allows specialists to predict, with great precision, the response that advanced-cancer patients will have to chemotherapy, as well as the associated secondary effects they may suffer.

4 Dec 2013

Oncology News and Research

Further Reading

Baylor researchers study outcomes and effectiveness of traumatic brain injury rehabilitation

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

Approaches to pain measurement used in cancer oncology clinical trials submitted to U.S. FDA

Researchers identify biomarker that may accurately predict prostate cancer spread

Cancer triggers scleroderma, shows evidence

Alvotech to invests $250M in the development of biosimilar monoclonal antibodies

IDSA released new guideline for vaccination of immunocompromised hosts

BIDMC study shows carbon monoxide may have a role to play in treating cancer

Lung cancer is costliest cancer in European Union

Roche signs research collaboration and licensing agreement with Molecular Partners

Laboratoire Cerba launches noninvasive prenatal test in multiple countries

Health Media Network, Digital Blue Dog partner to create Oncology point-of-care network in the U.S.

VolitionRx's two-assay test can detect 85% of colorectal cancer, more than 50% of precancerous polyps

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Allegiance Health, UMHS sign letter of intent to serve Jackson community

Cell Therapeutics concludes agreement with GKV-SV regarding reimbursement price of PIXUVRI

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Findings could have important implications for personalized treatment of colon cancer

Presence of ERG protein in biopsied prostate tissue increases likelihood of cancer development

CTCs serve as clinical tool to determine patient’s response to chemotherapy

Industry Focus eBook - Oncology (3rd edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News